Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData
Provider: Directors Deals Ltd.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Adocia SAS confirms positive clinical results for BioChaperone Combo, combination of long-acting insulin glargine and fast-acting insulin lispro

Thursday, 20 Mar 2014 02:54am EDT 

Adocia SAS:Positive final results for first clinical trial on innovative formulation combining insulin analog glargine (Lantus, Sanofi), gold standard basal insulin, with a rapid-acting insulin analog, lispro (Humalog, Eli Lilly) using Adocia's BioChaperonetechnology.BioChaperone technology enables solubilization of insulin glargine at physiological pH, which allows its combination in solution with prandial insulins analogs such as lispro.Eight patent applications have been filed to protect this innovation until 2032.Objective of this trial was to compare Pharmacodynamics (PD) and Pharmacokinetics (PK) of BioChaperone Combo with premix formulation of an insulin analog (Humalog Mix, lispro and protamine, Eli Lilly).In this double-blind crossover study, PK/PD characteristics of BioChaperone Combo (insulin glargine 75 pct and insulin lispro 25 pct) were investigated.Twenty people with type 1 diabetes received single 0.8 U/kg doses of BioChaperone Combo and Humalog Mix25 under automated euglycemic clamp conditions (ClampArt, target blood glucose (BG) 100 mg/dL, clamp duration 30 h post-dosing).